Christine Lovly Archives
Advocacy group’s gift boosts lung cancer research efforts
Feb. 13, 2020—An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.
Study reframes approach to targeted therapy resistance
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
Investigators map genomic landscape of very rare cancer
Feb. 28, 2019—A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
VUMC celebrates personalized care successes, charts course for FY19
Aug. 2, 2018—During the August Leadership Assembly at Vanderbilt University Medical Center, patients whose lives have been restored through personalized care shared their emotional stories, illustrating the Medical Center’s longtime commitment to use the latest advancements in genomic medicine as a powerful tool to tailor care to the individual.
Lung cancer patients and advocates visit VUMC research labs
Jun. 14, 2018—A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
Lovly earns scholarship grant for lung cancer research
Mar. 8, 2018—Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer.
Liquid biopsies help reveal lung cancer mutations
Nov. 2, 2017—Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC).
VU scientists discuss cancer treatments, cellular dynamics
Sep. 28, 2017—A trio of Vanderbilt University scientists described their cutting-edge investigations of cellular dynamics and cancer treatment during last week’s Flexner Discovery Lecture.
Trio of Vanderbilt scientists set for Discovery Lecture
Sep. 14, 2017—Three Vanderbilt University scientists on the forefront of research in cellular dynamics and cancer treatment will discuss their cutting-edge investigations during the next Flexner Discovery Lecture on Thursday, Sept. 21.
Lovly elected to American Society for Clinical Investigation
May. 4, 2017—Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI).
Vanderbilt’s Christine Lovly elected to American Society for Clinical Investigation
Apr. 24, 2017— Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt University Medical Center (VUMC), has been elected to The American Society for Clinical Investigation (ASCI). The ASCI is an elite honor society of physician-scientists. The Society, founded in 1908, is home to nearly 3,000 members from the upper ranks of academic...
VICC trial putting lung cancer therapy to the test
Oct. 20, 2016—Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.
